Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash from Financing Activities (2016 - 2025)

Vistagen Therapeutics' Cash from Financing Activities history spans 14 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 80.36% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $33.2 million, up 3677.59%, while the annual FY2025 figure was $3.2 million, 97.5% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.1 million at Vistagen Therapeutics, down from $27.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $93.7 million in Q4 2023 and bottomed at -$380000.0 in Q1 2024.
  • The 4-year median for Cash from Financing Activities is $1.7 million (2025), against an average of $11.8 million.
  • The largest annual shift saw Cash from Financing Activities plummeted 98.75% in 2024 before it soared 1590.91% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $8.3 million in 2021, then surged by 1023.64% to $93.7 million in 2023, then tumbled by 98.75% to $1.2 million in 2024, then skyrocketed by 80.36% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Cash from Financing Activities are $2.1 million (Q4 2025), $27.7 million (Q3 2025), and $1.5 million (Q2 2025).